Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo, Mario Annunziata, Ester Maria Orlandi, Sara Galimberti, Gianni Binotto, Nicola Sgherza, Luigia Luciano, Bruno Martino, Antonella Russo Rossi, Massimiliano Bonifacio, Claudio Fozza, Malgorzata Monika Trawinska, Daniele Cattaneo, Chiara Elena, Claudia Baratè, Fiorenza De Gregorio, Matteo MolicaGiorgio La Nasa, Robin Foà, Massimo Breccia

Research output: Contribution to journalArticle

Abstract

There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.

Original languageEnglish
Pages (from-to)1885-1890
JournalAnnals of Hematology
Volume98
Issue number8
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • Acetylsalicylic acid
  • Bosutinib
  • Cardiovascular risk
  • Chronic myeloid leukemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice'. Together they form a unique fingerprint.

  • Cite this

    Caocci, G., Mulas, O., Abruzzese, E., Iurlo, A., Annunziata, M., Orlandi, E. M., Galimberti, S., Binotto, G., Sgherza, N., Luciano, L., Martino, B., Russo Rossi, A., Bonifacio, M., Fozza, C., Trawinska, M. M., Cattaneo, D., Elena, C., Baratè, C., De Gregorio, F., ... Breccia, M. (2019). Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Annals of Hematology, 98(8), 1885-1890. https://doi.org/10.1007/s00277-019-03705-y